10x Genomics Launches Atara Platform but Revenue Growth Still Depends on Second Half Execution
10x Genomics (TXG) reports second-quarter 2026 earnings after the close on August 6, 2026, with analysts expecting a loss of $0.23 per share on revenue of approximately $146.7 million. The central question for investors: can the genomics tools provider sustain its recent streak of earnings surprises while navigating a challenging year-over-year comparison and demonstrating progress toward profitability? With the stock trading at $47.46 and up nearly 99% over the past 200 days, expectations are elevated heading into this release.
Part 1: Earnings Preview
10x Genomics develops and manufactures integrated systems for biological analysis, specializing in single-cell and spatial genomics solutions used in life science research and clinical applications. The company's platforms enable researchers to analyze biological systems at unprecedented resolution, serving pharmaceutical, biotechnology, and academic customers worldwide.
The company reports Q2 2026 earnings after market close on August 6, 2026, with the consensus estimate calling for a loss of $0.23 per share on revenue of $146.7 million. In the most recent quarter (Q1 2026), 10x Genomics reported a loss of $0.10 per share, beating estimates by 65.52% and delivering revenue of $150.8 million that exceeded expectations by 3.05%. However, the year-over-year comparison presents a significant challenge: in Q2 2025, the company reported earnings of $0.28 per share, meaning analysts expect a swing to a $0.23 loss — representing -182.14% year-over-year growth.
Three key themes define this earnings story:
Revenue Trajectory and Market Demand: After delivering four consecutive quarters of revenue beats, investors are watching whether 10x Genomics can maintain momentum despite a difficult comparison to Q2 2025's $172.9 million in revenue (which would represent a -15.21% year-over-year decline). The company's May guidance maintained its full-year 2026 revenue forecast of $600-625 million, suggesting management confidence despite near-term headwinds. The question is whether demand for single-cell and spatial genomics tools remains resilient amid broader life sciences spending pressures.
Path to Profitability: The expected swing from a $0.28 profit in Q2 2025 to a $0.23 loss in Q2 2026 represents a critical inflection point. With full-year 2026 estimates calling for a loss of $0.78 per share (compared to -$0.43 in 2025), investors need clarity on the timeline for returning to sustainable profitability and what operational improvements are driving the projected improvement to a -$0.65 loss in 2027.
Competitive Positioning in Spatial Genomics: As the spatial biology market evolves rapidly, 10x Genomics faces increasing competition from both established players and emerging technologies. Investors will scrutinize commentary on market share trends, new product adoption rates, and the company's ability to maintain its technology leadership in an increasingly crowded field.
Analyst commentary ahead of the release reflects cautious optimism tempered by valuation concerns. The consensus among 16 analysts shows 6 Strong Buys and 10 Holds, with a mean price target of $40.43 — notably below the current trading price of $47.46. This suggests the recent rally may have outpaced fundamental expectations, placing additional pressure on the company to deliver results that justify the valuation.
Part 2: Historical Earnings Performance
10x Genomics has established a strong pattern of exceeding analyst expectations over the past four quarters, though the magnitude and consistency of beats have varied significantly. The company has beaten EPS estimates in all four of the most recent quarters, with surprise percentages of +180.00%, +18.52%, +31.58%, and +65.52% respectively.
The Q2 2025 result stands out dramatically: the company reported earnings of $0.28 per share against expectations of a $0.35 loss, delivering a massive 180% positive surprise. This represented an unusual period of profitability that has not been sustained in subsequent quarters. The following three quarters returned to losses, though each beat lowered expectations — Q3 2025 posted -$0.22 versus -$0.27 expected, Q4 2025 delivered -$0.13 versus -$0.19 expected, and Q1 2026 came in at -$0.10 versus -$0.29 expected.
The trend suggests improving operational performance relative to expectations, with losses narrowing more quickly than analysts anticipated. However, the year-over-year comparison for the upcoming Q2 2026 report presents a significant challenge: analysts expect a $0.23 loss compared to the $0.28 profit delivered in the same quarter last year. This sets up a difficult narrative hurdle even if the company beats the lowered bar, as the absolute performance represents deterioration from the prior-year period.
| Quarter | EPS Estimate | EPS Actual | Surprise % | Beat/Miss |
|---|---|---|---|---|
| Jun 2025 | $-0.35 | $0.28 | +180.00% | Beat |
| Sep 2025 | $-0.27 | $-0.22 | +18.52% | Beat |
| Dec 2025 | $-0.19 | $-0.13 | +31.58% | Beat |
| Mar 2026 | $-0.29 | $-0.10 | +65.52% | Beat |
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
10x Genomics reports after market close, meaning Day 0 reflects pre-announcement anticipation while Day +1 captures the market's first full reaction to results.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-05-07 | -$0.32 (-1.41%) | $0.82 (3.63%) | -$0.82 (-3.66%) | $2.17 (9.68%) |
| 2026-02-12 | -$1.64 (-8.56%) | $1.89 (9.87%) | +$0.61 (+3.48%) | $3.25 (18.56%) |
| 2025-11-06 | -$0.49 (-3.63%) | $0.56 (4.15%) | +$2.25 (+17.31%) | $1.68 (12.92%) |
| 2025-08-07 | +$0.14 (+1.11%) | $0.58 (4.62%) | -$0.51 (-3.98%) | $2.61 (20.39%) |
| 2025-05-08 | +$0.32 (+3.85%) | $0.63 (7.58%) | +$0.14 (+1.62%) | $1.82 (21.09%) |
| 2025-02-12 | +$0.18 (+1.52%) | $0.70 (5.96%) | -$0.06 (-0.50%) | $1.25 (10.42%) |
| 2024-10-29 | -$0.07 (-0.44%) | $0.72 (4.53%) | +$0.70 (+4.43%) | $1.87 (11.84%) |
| 2024-08-08 | +$1.42 (+7.83%) | $1.48 (8.16%) | +$0.88 (+4.50%) | $2.05 (10.51%) |
| Avg Abs Move | 3.54% | 6.06% | 4.94% | 14.43% |
Historical price behavior around earnings shows moderate Day 0 volatility averaging 3.54% in absolute terms, with a typical intraday range of 6.06% as traders position ahead of the after-hours release. The Day +1 reaction has been more pronounced, with an average absolute move of 4.94% and a wider average range of 14.43%, reflecting the market's full digestion of results and guidance.
Recent earnings have shown mixed directional patterns. The most recent Q1 2026 report saw minimal Day 0 movement (-1.41%) followed by a modest Day +1 decline (-3.66%), despite the company beating estimates. In contrast, Q3 2025 delivered a dramatic Day +1 surge of +17.31% after results, demonstrating the stock's capacity for significant post-earnings moves when results and guidance exceed expectations. The Q2 2025 report — the comparable period to the upcoming release — showed relatively muted Day 0 movement (+1.11%) but a -3.98% Day +1 decline, suggesting investors may have been disappointed despite the strong absolute results.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 08/21/26 (DTE 16) |
| Expected Move | $7.85 (16.55%) |
| Expected Range | $39.61 to $55.31 |
| Implied Volatility | 116.38% |
The options market is pricing an expected move of 16.55% (±$7.85) for the August 21 expiration, significantly higher than both the historical Day 0 average move of 3.54% and the Day +1 average of 4.94%. This elevated implied volatility of 116.38% suggests options traders are anticipating substantially larger price swings than the stock has typically delivered around recent earnings events, potentially reflecting heightened uncertainty around the difficult year-over-year comparison or increased speculation given the stock's strong recent run.
Part 3: What Analysts Are Saying
The analyst community maintains a cautiously optimistic stance on 10x Genomics, with the consensus rating at 3.75 (between Hold and Buy) and an average price target of $40.43. Among 16 analysts covering the stock, 6 rate it a Strong Buy while 10 assign Hold ratings, with no Sell or Strong Sell recommendations. Price target estimates range from a low of $25.00 to a high of $50.00, reflecting divergent views on the company's valuation and growth prospects.
Analyst sentiment has remained unchanged over the past month, with the distribution of ratings and average recommendation holding steady at 3.75. This stability suggests analysts are taking a wait-and-see approach heading into the Q2 report, neither upgrading in anticipation of strong results nor downgrading due to concerns about the difficult comparison.
The consensus price target of $40.43 implies 14.8% downside from the current price of $47.46, a notable disconnect that suggests the stock's recent rally has outpaced analyst expectations. This creates an interesting dynamic heading into earnings: even if 10x Genomics beats estimates and delivers positive guidance, the stock may face resistance if results don't justify the premium valuation it has achieved. The high-end price target of $50.00 offers only 5.4% upside, while the low-end target of $25.00 represents 47.3% downside risk, underscoring the wide range of potential outcomes analysts see for the stock.
Part 4: Technical Picture
10x Genomics enters the earnings release with strong technical momentum firmly intact. The Barchart Technical Opinion registers a 100% Buy signal, unchanged from both one week ago and one month ago, indicating sustained bullish conviction across all timeframes. This maximum-strength reading reflects the stock's powerful advance from lower levels and suggests technical buyers remain in control heading into the report.
Timeframe Analysis:
- Short-term (100% Buy): Maximum buy signal indicates powerful near-term momentum with no signs of exhaustion
- Medium-term (100% Buy): Continued strength in the intermediate timeframe confirms the uptrend is well-established beyond just short-term speculation
- Long-term (100% Buy): Full buy signal across the longest timeframe suggests the stock has transitioned into a sustained bull market phase
Trend Characteristics: The technical environment shows Maximum strength with a Strengthening direction, indicating not only that the uptrend is firmly established but that momentum continues to build heading into the earnings event.
The stock trades above all major moving averages, a textbook bullish configuration. At $47.46, TXG sits above its 10-day ($47.26), 20-day ($45.87), 50-day ($37.99), 100-day ($29.84), and 200-day ($23.89) moving averages, though it has pulled back slightly below the 5-day average ($47.81). The widening gaps between the current price and longer-term averages — particularly the 98.7% premium to the 200-day — illustrate the magnitude of the rally over the past several months.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $47.81 | 50-Day MA | $37.99 |
| 10-Day MA | $47.26 | 100-Day MA | $29.84 |
| 20-Day MA | $45.87 | 200-Day MA | $23.89 |
The technical setup heading into earnings is decidedly supportive but stretched. While the alignment of moving averages and maximum buy signals across all timeframes provide a favorable backdrop, the stock's position nearly 100% above its 200-day moving average suggests limited room for disappointment. The slight pullback below the 5-day moving average at $47.81 may represent near-term resistance, while the 10-day average at $47.26 has provided recent support. Given the options market's expectation of a 16.55% move and the stock's extended valuation relative to analyst price targets, the technical picture suggests earnings could serve as either a breakout catalyst above $50 or a profit-taking event that tests support in the $45-46 range.
